Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets

[1]  P. Agius,et al.  Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With Rheumatoid Arthritis in Clinical Remission , 2019, Arthritis & rheumatology.

[2]  J. Smolen,et al.  Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. , 2019, Rheumatology.

[3]  J. Smolen,et al.  Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition , 2017, Arthritis Research & Therapy.

[4]  J. Smolen,et al.  Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria , 2017, Arthritis & rheumatology.

[5]  Yoshiya Tanaka,et al.  Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study , 2013, Annals of the rheumatic diseases.

[6]  T. Kohlmann,et al.  Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[7]  J. Smolen,et al.  Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. , 2011, Arthritis and rheumatism.

[8]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[9]  M. Østergaard,et al.  Does Clinical Remission Lead to Normalization of EQ-5D in Patients with Rheumatoid Arthritis and Is Selection of Remission Criteria Important? , 2010, The Journal of Rheumatology.